TY - JOUR
T1 - Effect of muscimol on glucose-stimulated somatostatin and insulin release from the isolated, perfused rat pancreas
AU - Robbins, M. S.
AU - Grouse, L. H.
AU - Sorenson, Robert L
AU - Elde, R. P.
PY - 1981
Y1 - 1981
N2 - This study examines the effect of muscimol, a high affinity, specific gamma-aminobutyric acid (GABA) agonist, on glucose-stimulated somatostatin and insulin release from the isolated, perfused rat pancreas. Perfusion with low glucose (50 mg/dl) conditions resulted in basal somatostatin release of 46 ± 4 pg/ml. Basal insulin release was less than 20 μU/ml. High glucose (300 mg/dl) conditions stimulated somatostatin and insulin release. Steady-state levels of somatostatin and insulin release under high glucose conditions were 425 ± 12 pg/ml and 419 ± 18 μU/ml, respectively. Perfusion with medium containing 1 μM muscimol inhibited glucose-stimulated somatostatin release by 38%, whereas the course of glucose-stimulated insulin release was unaffected. Tentative conclusions from this study are (1) that GABA is potentially a modulator of islet somatostatin but not insulin release, and (2) the fact that somatostatin, an inhibitor of insulin, can be suppressed 38% without coincidental increase in insulin release seems to indicate that, under high glucose conditions, somatostatin is without a significant paracrine effect on the beta-cells.
AB - This study examines the effect of muscimol, a high affinity, specific gamma-aminobutyric acid (GABA) agonist, on glucose-stimulated somatostatin and insulin release from the isolated, perfused rat pancreas. Perfusion with low glucose (50 mg/dl) conditions resulted in basal somatostatin release of 46 ± 4 pg/ml. Basal insulin release was less than 20 μU/ml. High glucose (300 mg/dl) conditions stimulated somatostatin and insulin release. Steady-state levels of somatostatin and insulin release under high glucose conditions were 425 ± 12 pg/ml and 419 ± 18 μU/ml, respectively. Perfusion with medium containing 1 μM muscimol inhibited glucose-stimulated somatostatin release by 38%, whereas the course of glucose-stimulated insulin release was unaffected. Tentative conclusions from this study are (1) that GABA is potentially a modulator of islet somatostatin but not insulin release, and (2) the fact that somatostatin, an inhibitor of insulin, can be suppressed 38% without coincidental increase in insulin release seems to indicate that, under high glucose conditions, somatostatin is without a significant paracrine effect on the beta-cells.
UR - http://www.scopus.com/inward/record.url?scp=0019402937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019402937&partnerID=8YFLogxK
U2 - 10.2337/diab.30.2.168
DO - 10.2337/diab.30.2.168
M3 - Article
C2 - 6110597
AN - SCOPUS:0019402937
SN - 0012-1797
VL - 30
SP - 168
EP - 171
JO - Diabetes
JF - Diabetes
IS - 2
ER -